# Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

> **NCT02874989** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 26 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** Dasatinib + Quercetin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02874989
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-16
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874989, "Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02874989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*